Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89396 | 0.81 | SLC6A2 (0.41) | SLC6A4SLC6A2SLC6A3KMT2AKDM4E | |
| SCHEMBL16455678 | 0.76 | AAK1 (0.39) | KDM4ETSHRLMNAHTTALDH1A1 | |
| SCHEMBL4128579 | 0.76 | UHRF1 (0.43) | SLC6A4SLC6A2SLC6A3UHRF1ALDH1A1 | |
| SCHEMBL25009568 | 0.74 | MCHR1 (0.38) | SLC6A4SLC6A2SLC6A3UHRF1KCNH2 | |
| SCHEMBL27857265 | 0.73 | CYP17A1 (0.36) | SLC6A2KMT2AKDM4EKCNH2LMNA | |
| SCHEMBL19491483 | 0.73 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3UHRF1KMT2A | |
| SCHEMBL89387 | 0.72 | TSHR (0.62) | KMT2AKDM4ETSHRLMNAHTT | |
| Hydrochloric Acid SCHEMBL28832301 | 0.71 | ALDH1A1 (0.37) | SLC6A2KMT2AKDM4EKCNH2LMNA | |
| SCHEMBL7868146 | 0.71 | CRHR1 (0.39) | — | |
| SCHEMBL13433964 | 0.71 | L3MBTL1 (0.44) | KMT2AEHMT2MEN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | SLC6A4 895/4885SLC6A2 640/4885SLC6A3 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.